MTERF3

Across TCGA pan-cancer cohorts, MTERF3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MTERF3 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher MTERF3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MTERF3 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, LUAD, and COAD are the cancer types where MTERF3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	1.000	0.837	.006	19	view →
LUAD	DFS	Tertile	III,IV	0.847	0.156	.006	16	view →
COAD	DFS	Median	All	1.000	0.894	.036	12	view →
CCRCC	DFS	Tertile	III,IV	0.817	1.000	.033	5	view →
UCEC	OS	Median	All	0.847	0.963	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MTERF3–LSCC (DFS)

Open the LSCC breakdown →